RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Bavarian Reperfusion Alternatives Evaluation-3 Trial
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 2
SP 9
OP 10
DO 10.1177/155989770800800206
UL http://mdc.sagepub.com/content/8/2/9.2.abstract
AB For patients with acute ST-elevation myocardial infarction (STEMI) who undergo primary coronary intervention, the addition of abciximab does not enhance the clinical benefits that are provided by pretreatment with high-dose clopidogrel, according to the findings of the Bavarian Reperfusion Alternatives Evaluation-3 [BRAVE-3] trial. Moreover, abciximab increases the risk of adverse clinical outcomes, suggesting that it should not be added to standard antiplatelet therapy in this patient population.